Axsome Therapeutics (NASDAQ:AXSM) has received diverse analyst ratings over the last three months, with a notable increase in the average 12-month price target to $131.38 from $90.00, indicating a 45.98% rise. The company, a clinical-stage biopharmaceutical firm focusing on CNS disorders, has shown a significant revenue growth rate of 243.07% as of September 30, 2023. However, it faces challenges with a net margin of -107.62% and below-average ROE and ROA. Analysts from firms like UBS, RBC Capital, Cantor Fitzgerald, Piper Sandler, HC Wainwright & Co., and Citigroup have provided ratings ranging from Buy to Overweight, with price targets up to $180.00.